1-3 of 3
Teresa M. O’Brien
Close
Sort by
Journal Articles

A Prospective Study Evaluating the Safety and Efficacy of Combination Therapy with Fludarabine Plus Mitoxantrone Followed by Yttrium-90 ( 90 Y) Ibritumomab Tiuxetan (Zevalin®) and Maintenance Rituximab as Front Line Therapy for Patients with Intermediate or High Risk Follicular Non-Hodgkin’s Lymphoma.

Stephanie A. Gregory, MD, Mohamad Kassar, M.D., Henry C. Fung, M.D., Parameswaran Venugopal, M.D., Teresa M. O’Brien, Michelle Tenuto
Journal: Blood
Blood (2007) 110 (11): 1360.
https://doi.org/10.1182/blood.V110.11.1360.1360
Published: 2007
Journal Articles

Safety and Efficacy of Fludarabine Plus Mitoxantrone (FM) Followed by Yttrium-90 ( 90 Y) Ibritumomab Tiuxetan (Zevalin ® ) and Maintenance Rituximab in Intermediate- to High-Risk Newly Diagnosed and Relapsed Follicular Non-Hodgkin’s Lymphoma (NHL).

Stephanie A. Gregory, MD, Parameswaran Venugopal, MD, Jamile M. Shammo, MD, Teresa M. O’Brien, RN, Amjad Ali, MD
Journal: Blood
Blood (2005) 106 (11): 4789.
https://doi.org/10.1182/blood.V106.11.4789.4789
Published: 2005
Journal Articles

Radioimmunotherapy with I 131 Tositumomab in Relapsed and Transformed Low-Grade (LG) Non-Hodgkin’s Lymphoma (NHL): Long-Term Follow-Up of a Single Institution Experience.

Huma Qawi, Teresa M. O’Brien, Parameswaran Venugopal, Jamile Shammo, Elena Bogdanova, Stephanie A. Gregory
Journal: Blood
Blood (2004) 104 (11): 4641.
https://doi.org/10.1182/blood.V104.11.4641.4641
Published: 2004